Compare conditions

Put any two — or three — conditions side by side, adult or pediatric, to spot the look-alike differences fast, row by row.

Prostate Cancer

—

In one line

·Prostate cancer is very common, usually grows slowly, and often needs watching more than treating right away.

—

Normal physiology

·The prostate is a walnut-sized gland that sits just below the bladder and wraps around the urethra, the tube that carries urine out of the body. Its job is to make a milky fluid that mixes with sperm during ejaculation to help the sperm survive and swim.

—

What goes wrong

·Cells in the prostate start growing out of control, forming a tumor that can squeeze the urethra, invade nearby organs, or spread to bones.

—

Hallmark signs

·Weak urine stream or trouble starting to pee
·Needing to pee often, especially at night
·Blood in the urine or semen
·Pain in the lower back, hips, or pelvis that does not go away
·Trouble getting or keeping an erection
·Painful ejaculation
·Raised PSA on a blood test
·Hard lump or uneven area felt during a digital rectal exam

—

Red flags · escalate now

·Blood in the urine or semen
·Bone pain in the back, hips, or pelvis that does not go away
·Sudden trouble holding urine or moving your legs (could mean the cancer is pressing on the spinal cord)
·Unexplained weight loss and deep tiredness
·PSA rising very fast or staying high after treatment

—

Workup

·PSA (prostate-specific antigen) blood test
·Digital rectal exam (DRE)
·Prostate MRI (multiparametric MRI)
·Prostate biopsy (transrectal or transperineal ultrasound-guided)
·Bone scan (technetium-99m scan)
·CT or PET scan (PSMA PET if available)
·Germline genetic testing for BRCA1, BRCA2, ATM, and other DNA-repair genes

—

Treatment

·PSA screening with shared decision-making for men age 55-69 (or starting at 40-45 for Black men or those with family history)
·Active surveillance (PSA every 3-6 months, repeat MRI and biopsy every 1-3 years) for Gleason 6 or low-volume Gleason 7 cancer confined to the prostate
·Radical prostatectomy (surgery to remove the entire prostate and seminal vesicles) for localized intermediate- or high-risk cancer
·External beam radiation therapy (often with brachytherapy seed implants for boost) for localized intermediate- or high-risk cancer
·Androgen deprivation therapy (ADT): GnRH agonists (leuprolide, goserelin) or antagonists (degarelix, relugolix) to block testosterone
·Chemotherapy (docetaxel or cabazitaxel) for metastatic castration-resistant prostate cancer
·PARP inhibitors (olaparib, rucaparib) for metastatic castration-resistant cancer with BRCA1, BRCA2, or ATM mutations

—

NCLEX trap

·Elevated PSA is a flag, not a diagnosis. PSA can be high from prostate cancer, from infection (prostatitis), from benign enlargement (BPH), or simply from being over age 50. You need a biopsy to know for sure. Not every man with high PSA needs surgery — low-risk cancer may need only watching and waiting (active surveillance). PSA is one clue that tells you to look closer, not to jump to surgery.
·Many men with early prostate cancer have NO symptoms at all. Screening with PSA and digital rectal exam (DRE) catches cancer before symptoms appear. Late symptoms — trouble peeing, bone pain, or blood in the urine — mean cancer has already spread outside the prostate or pressed on nearby parts. Absence of symptoms does not rule out prostate cancer; it just means it is early.
·PSA screening is not one-size-fits-all. Men aged 55–69 with average or high risk may benefit from a talk about screening (shared decision-making per USPSTF). Black men and men with a father or brother who had prostate cancer should start the talk at age 40–45 (ACS/AUA). Men over 75 or with less than 10 years of expected life often should not be screened because overdiagnosis and treatment side effects outweigh benefit. The decision is shared, weighing benefit and harm.
·Prostate cancer is often slow-growing. Many men live 10, 20, or 30 years with it, especially if caught early. Low-risk prostate cancer (Gleason 6, PSA <10, stage T1c–T2a) may never cause death — these men often die with it, not from it. High-risk or advanced cancer (Gleason 8–10, high PSA, or spread to bones) spreads faster and is more serious. Life span depends on risk group (NCCN stratifies low/intermediate/high/very-high), age, and how well treatment works.
·Hormone therapy shrinks advanced prostate cancer and controls it for months to years by blocking testosterone (the fuel prostate cancer cells need), but it does not cure it. Prostate cancer cells eventually become resistant — this is called castration-resistant prostate cancer (CRPC). Then other drugs (chemotherapy like docetaxel, new hormone agents like abiraterone or enzalutamide, or PARP inhibitors for BRCA mutations) may help. Hormone therapy buys time and quality of life, not a cure.
·Black men have higher risk for prostate cancer (almost twice the incidence of white men) and die from it more often (twice the death rate per ACS). Risk talk should start at age 40–45 for Black men, even without family history (ACS/AUA). Age plus race genetics matter — studies show earlier onset and more aggressive disease in this group. Shared decision-making about screening benefits and risks is the right approach.

—

Install Maldek by Hill as an app — studies work even offline